Fundraising FoxAvedro, Inc.
Foundationalso invests · investor profileAcquiredWaltham, US · Delaware corporation · 13 known investors
Find your way into Avedro, Inc.
Sign up to see every warm intro you have to Avedro, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avedro, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avedro is an ophthalmic company focused on corneal health, known for bio-activated cross-linking therapies such as the KXL system and riboflavin-based treatments used to address progressive keratoconus. It was acquired in 2019 by Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company developing glaucoma, corneal and retinal therapies, and now operates as part of Glaukos, whose website the avedro.com domain serves.
Founders & leadership
Board
Investors · 13
How we know: APERTURE Venture Partners's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: Third Point Ventures's portfolio page · Not right? Tell us
How we know: westerntech.com · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · lavfund.com · Not right? Tell us
How we know: a partner's Signal profile · funding news · lavfund.com · Not right? Tell us
How we know: biospace.com · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$93.3M disclosed across 5 of 6 rounds · 2011–2018
▶$25MraisedMay 2018 · 19 investors · Other Health CareRule 506(b)
- Jonathan SilversteinDirector
- Gilbert KlimanDirector
- Garheng KongDirector
- Reza ZadnoExecutive Officer, Director
- Robert PalmisanoDirector
- Hongbo LuDirector
- Joseph MandatoDirector
- Donald ZurbayDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedMay 2017 · 14 investors · Other Health CareRule 506(b)
- REZA ZADNOExecutive Officer, Director
- PAUL BAVIERExecutive Officer
- GILBERT H. KLIMANDirector
- JOSEPH MANDATODirector
- JONATHAN SILVERSTEINDirector
- TOM GRIFFINExecutive Officer
- ROBERT PALMISANODirector
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.5MraisedNov 2015 · 23 investors · Other Health CareRule 506(b)
- Steve BlinnExecutive Officer
- David F. MullerExecutive Officer, Director
- Jeff DykanDirector
- M. Carl Johnson, IIIDirector
- Brian J. RobertsExecutive Officer
- Anthony NataleDirector
- Robert PalmisanoDirector
- Joseph MandatoDirector
- Philip J. FerneauDirector
- Offering amount
- $32M
- Amount sold
- $16.5M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.7MraisedApr 2015 · 22 investors · Other Health CareRule 506(b)
- Jason HongDirector
- David F. MullerExecutive Officer, Director
- Jeff DykanDirector
- Anthony NataleDirector
- Robert PalmisanoDirector
- Philip J. FerneauDirector
- M. Carl Johnson, IIIDirector
- David BerryDirector
- Michael BighamDirector
- Brian J. RobertsExecutive Officer
- Joseph MandatoDirector
- Offering amount
- $17.6M
- Amount sold
- $13.7M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$26MraisedFeb 2012 · 23 investors · Other Health CareRule 506(b)
- David F. MullerExecutive Officer, Director
- Philip J. FerneauDirector
- Anthony NataleDirector
- Rhonda J. BraceyExecutive Officer
- Doug ColeDirector
- Jeff DykanDirector
- Joseph MandatoDirector
- M. Carl Johnson, IIIDirector
- Offering amount
- $26M
- Amount sold
- $26M
- Finders' fees
- $478.1K
- Placement agents
- BMO Capital Markets Corp.
- First sale
- Jun 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Avedro, Inc. went on to found or lead other companies.
In the news
Frequently asked questions
- What does Avedro, Inc. do?
- Avedro is an ophthalmic company focused on corneal health, known for bio-activated cross-linking therapies such as the KXL system and riboflavin-based treatments used to address progressive keratoconus. It was acquired in 2019 by Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company developing glaucoma, corneal and retinal therapies, and now operates as part of Glaukos, whose website the avedro.com domain serves.
- Who founded Avedro, Inc.?
- Avedro, Inc. was founded by David F. Muller.
- Who are Avedro, Inc.'s investors?
- Avedro, Inc.'s investors include APERTURE Venture Partners, LAV, Lilly Asia Ventures, SCP Vitalife Partners, Third Point Ventures, Western Technology Investment, Abingworth, Borealis Ventures and 4 more.
- How much funding has Avedro, Inc. raised?
- Avedro, Inc. has disclosed $93.3M raised across 5 of its 6 known rounds.
- Where is Avedro, Inc. headquartered?
- Avedro, Inc. is headquartered in Waltham, US.